Overview: FISH Gender Confirmation Panel
Introduction: The FISH Gender Confirmation Panel is a diagnostic tool designed to confirm gender in ambiguous genitalia using whole blood samples. In India, disorders of sex development (DSD) with sex reversal (e.g., 46,XY females or 46,XX males) are underdiagnosed (~1 in 5,000â€"10,000 births), often presenting with ambiguous genitalia, delayed puberty, or infertility. High morbidity from under-testing in rural/low-SES infants/children, limited genetic labs, delayed hormone therapy/gender assignment leading to psychological distress, social stigma, or gonadal malignancy risk. Per cytogenetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs FISH for sex chromosome analysis over 1-2 days with high sensitivity/specificity, valuable for rapid sex determination in DSD workup. This diagnostic falls under genetic screening and targets newborns/children with ambiguous genitalia or sex reversal suspicion, addressing accurate detection to guide multidisciplinary management (endocrinology, psychology, surgery) and parental counseling. With elevated morbidity due to underdiagnosis and cultural barriers, the test supports public health efforts by enabling precise chromosomal confirmation and reducing long-term complications. Its whole blood-based approach ensures reliable sex chromosome detection.
Other Names: FISH Gender Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.
Historical Milestone: Sex chromosome FISH for DSD; in India, used in pediatric endocrinology.
Purpose: The test detects 2 parameters including sex chromosome analysis to guide gender confirmation, detect SRY/XY presence, inform management.
Test Parameters: 1. Sex Chromosome Analysis, 2. SRY Gene Detection.
Pretest Condition: No fasting required; patients should have suspected sex reversal or DSD.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for FISH).
Medical History: Patients should provide details on genital ambiguity, puberty delay, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed DSD including gender issues, benefits of confirmation, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: XY with SRY confirms male genetic sex; absence suggests other DSD etiology, necessitating specialist input.
Specialist Consultation: Pediatric endocrinologists or geneticists should be consulted for management.
Additional Supporting Tests: Karyotype, hormone levels for confirmation.
Test Limitations: Detects sex chromosomes/SRY only; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, DSD Studies India 2023.
